JP2006096730A - Wrinkle-improving agent - Google Patents

Wrinkle-improving agent Download PDF

Info

Publication number
JP2006096730A
JP2006096730A JP2004288160A JP2004288160A JP2006096730A JP 2006096730 A JP2006096730 A JP 2006096730A JP 2004288160 A JP2004288160 A JP 2004288160A JP 2004288160 A JP2004288160 A JP 2004288160A JP 2006096730 A JP2006096730 A JP 2006096730A
Authority
JP
Japan
Prior art keywords
wrinkle
improving agent
skin
present
protein fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004288160A
Other languages
Japanese (ja)
Inventor
Tomohiro Terauchi
友広 寺内
Kazuhiro Suetsugu
一博 末次
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naris Cosmetics Co Ltd
Original Assignee
Naris Cosmetics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naris Cosmetics Co Ltd filed Critical Naris Cosmetics Co Ltd
Priority to JP2004288160A priority Critical patent/JP2006096730A/en
Publication of JP2006096730A publication Critical patent/JP2006096730A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a wrinkle-improving agent having an excellent skin wrinkle-improving effect. <P>SOLUTION: This wrinkle-improving agent is characterized by comprising (A) at least one soluble protein fraction extracted from the seeds of Hibiscus esculentus and (B) a cell-activating ingredient. It was found that the wrinkle-improving action was synergistically increased when together using a cell activating components. The wrinkle-improving agent has a wrinkle-improving effect. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

本発明は、シワ改善剤に関し、詳しくは、皮膚のシワを改善する効果に優れると共に安全性の高いシワ改善剤およびこれを含有するシワ改善
効果に優れる皮膚化粧料に関する。
The present invention relates to a wrinkle improving agent, and more particularly, to a wrinkle improving agent having an excellent effect of improving skin wrinkles and having high safety, and a skin cosmetic having an excellent wrinkle improving effect containing the same.

技術背景Technical background

一般的に、シワの形成は、紫外線や化学薬品、物理刺激等の外部刺激、乾燥等の外部環境、及び加齢等の種々の要因が複雑に影響し合って起こることが知られている。   In general, it is known that wrinkle formation is caused by various influences such as ultraviolet rays, chemicals, external stimuli such as physical stimuli, external environment such as drying, and various factors such as aging.

従来より、この様な皮膚におけるトラブルの改善を目的として、種々の化粧料や化粧料用素材が開発されてきた。例えば、ヒアルロン酸に代表される多糖類は、優れた保水作用を有しており、老化等により保水能力の低下した肌の保水能力を補助し、肌に潤いを与え肌荒れを防ぐことが知られている。しかしながら、種々の肌トラブルのうちシワに関しては、上皮細胞増殖因子(EGF)やコラーゲンを化粧料に配合してこれを改善しようとする試みがあるが、その効果は芳しいものではなかった。 Conventionally, various cosmetics and cosmetic materials have been developed for the purpose of improving such troubles in the skin. For example, polysaccharides typified by hyaluronic acid have an excellent water retention effect, and are known to assist the water retention capability of skin whose water retention capability has decreased due to aging, etc., to moisturize the skin and prevent rough skin. ing. However, with regard to wrinkles among various skin troubles, there have been attempts to improve this by adding epidermal growth factor (EGF) or collagen to cosmetics, but the effect has not been good.

また、細胞賦活目的や創傷治療目的の皮膚外用剤、即ち新陳代謝を活発にして皮膚の老化を防止するために用いられる皮膚外用剤の薬効成分としては、一般にアラントイン及びその誘導体、牛血液除蛋白物、アロエ抽出物、人参抽出物、胎盤抽出物などが用いられてきたが、これらの薬効成分を含む皮膚外用剤の皮膚老化防止作用は、必ずしも十分に満足のいくものではなく、このため、より優れた細胞賦活作用を有する皮膚外用剤の開発が望まれていた。 In addition, as a medicinal component of a skin external preparation for cell activation or wound treatment, that is, a skin external preparation used to activate metabolism and prevent skin aging, generally allantoin and its derivatives, bovine blood deproteinized products Aloe extract, ginseng extract, placenta extract, etc. have been used, but the anti-skinning action of the topical skin preparations containing these medicinal ingredients is not always fully satisfactory. Development of an external preparation for skin having an excellent cell activation effect has been desired.

一方、オクラ(Hibiscus esculentus)の種子から抽出された少なくとも1つの可溶性タンパク質画分を化粧品組成物又は化粧品に使用すると、皮膚に対して、強い細胞栄養力、滑らかにするバイオフィルム形成作用、コンディショニング、リストラクチャリング、及び修復作用、並びに抗刺激性、日光からの保護、鎮静、及び皮膚の老化防止作用が発見された。
特表2001−518910号公報
On the other hand, when at least one soluble protein fraction extracted from the seeds of okra (Hibiscus esculentus) is used in a cosmetic composition or cosmetic, it has a strong cellular nutritional force, a smoothing biofilm forming action, conditioning, Restructuring and restorative effects, as well as anti-irritant, sun protection, sedation, and anti-aging skin effects have been discovered.
JP-T-2001-518910

しかしながら、オクラ(Hibiscus
esculentus)の種子から抽出された少なくとも1つの可溶性タンパク質画分単独ではその効果を十分に発揮させることは難しく、また目的達成の為には多量に配合する必要があった。
However, okra (Hibiscus
The at least one soluble protein fraction extracted from the seeds of esculentus) is difficult to exert its effect sufficiently, and it is necessary to add a large amount to achieve the purpose.

係る実情において、本発明者らは、優れたシワ改善作用を有する皮膚外用剤を得るべく鋭意研究を重ねた結果、(A)オクラ(Hibiscus
esculentus)の種子 から抽出された少なくとも1つの可溶性タンパク質画分と(B)細胞賦活成分を併用すれば、シワ改善作用が相乗的に増大することを見いだし、本発明を完成した。即ち本発明は、(A)オクラ(Hibiscus
esculentus)の種子から抽出された少なくとも1つの可溶性タンパク質画分と(B)細胞賦活剤とを有効成分として含有することを特徴とするシワ改善剤を提供するものである。
Under such circumstances, the present inventors have conducted extensive research to obtain an external preparation for skin having an excellent wrinkle-improving action, and as a result, (A) Okra (Hibiscus)
It was found that when at least one soluble protein fraction extracted from seeds of (esculentus) and (B) a cell activation component were used in combination, the wrinkle improving action was synergistically increased, and the present invention was completed. That is, the present invention provides (A) Okra (Hibiscus)
The present invention provides a wrinkle improving agent comprising at least one soluble protein fraction extracted from seeds of (esculentus) and (B) a cell activator as active ingredients.

以下、本発明をより詳細に説明すると、本発明の(A)成分としてオクラ(Hibiscus
esculentus)の種子から抽出された少なくとも1つの可溶性タンパク質画分である。
Hereinafter, the present invention will be described in more detail. As component (A) of the present invention, okra (Hibiscus) is used.
esculentus) at least one soluble protein fraction extracted from seeds.

Hibiscus esculentus(Abelmoshus esculentus又はオアイ科のオクラ )は、「gambo(オクラ )」というスペイン語の名前で米国及び東インドに導入されたアフリカ起源の植物である。これは2,000年以上も前からそのさやを得るために栽培されて来た植物種の1つである。オクラ
は、世界の数多くの地域、例えばインド、マレーシア、フィリピン、アメリカ(中西部)、地中海地域、アフリカ、及びより一般的には熱帯地域において生育している。
Hibiscus esculentus (Abelmoshus esculentus or Ocraaceae okra) is a plant of African origin introduced in the United States and East India under the Spanish name “gambo”. This is one of the plant species that has been cultivated to obtain its pods for over 2,000 years. Okra grows in many parts of the world, such as India, Malaysia, the Philippines, the United States (midwest), the Mediterranean region, Africa, and more generally the tropical region.

本発明の(A)成分の調製法は特に限定されず、以下のどのタンパク画分を用いることができる。タンパク質画分が、様々なpHの水又は塩溶液によるHibiscus
esculentusの全種子又は殻が剥かれた種子の非脱脂又は脱脂穀から抽出することができる。また、タンパク質画分が、超音波の影響下、水溶液中に抽出されてもよい。また、タンパク質画分が、沈殿、吸着、イオン又はアフィニティ交換クロマトグラフィ、及び限外濾過から成る群から選ばれる精製プロセスによって精製したものや総タンパク質画分又は天然タンパク質画分が、ゲル上濾過された時に、見掛け分子量が1,000,000〜1,500,000Da、250,000〜350,000Da、130,000〜180,000Da、17,000〜22,000Da、3,300Da、及び2,300〜2,600Da、2,300〜1,000Da、1,000Da以下のものなどいかなる分子量のものを用いてもよい。また、タンパク質画分が、天然タンパク質から調製された化学的又は酵素的水解物からなるものでもよい。
The method for preparing the component (A) of the present invention is not particularly limited, and any of the following protein fractions can be used. Protein fraction is Hibiscus with various pH water or salt solutions
It can be extracted from the non-defatted or defatted grains of whole seeds or shelled seeds of esculentus. In addition, the protein fraction may be extracted into an aqueous solution under the influence of ultrasound. The protein fraction was purified by a purification process selected from the group consisting of precipitation, adsorption, ion or affinity exchange chromatography, and ultrafiltration, and the total protein fraction or the native protein fraction was filtered on a gel. Sometimes the apparent molecular weight is 1,000,000 to 1,500,000 Da, 250,000 to 350,000 Da, 130,000 to 180,000 Da, 17,000 to 22,000 Da, 3,300 Da, and 2,300 to Any molecular weight such as 2,600 Da, 2,300 to 1,000 Da, 1,000 Da or less may be used. Further, the protein fraction may be composed of a chemical or enzymatic hydrolyzate prepared from a natural protein.

本発明のにおいて、これらオクラ(Hibiscus
esculentus)の種子から抽出された少なくとも1つの可溶性タンパク質画分含有量は、特に限定されるものではないが、通常、シワ改善剤全体に対し、0.0001〜20質量%、好ましくは0.01〜10質量%、さらに好ましくは0.1〜1質量%の範囲で選定すると好適である。
In the present invention, these okra (Hibiscus)
The content of at least one soluble protein fraction extracted from the seeds of esculentus) is not particularly limited, but is usually 0.0001 to 20% by mass, preferably 0.01%, based on the whole wrinkle improving agent. It is suitable to select in the range of 10 to 10% by mass, more preferably 0.1 to 1% by mass.

本発明の(B)成分として用いられるアデノシン三リン酸
、アデノシン二リン酸、アデノシン一リン酸(以下、それぞれATP、ADP、AMPという)は、生体内でエネルギー伝達系、生成系に関与する物質である。本発明においては、これらATP、ADP、AMPの他、これらの塩やエステル等の誘導体も使用することができ、例えば、ATP、ADP又はAMPの一ナトリウム塩、二ナトリウム塩、三ナトリウム塩、一カリウム塩、二カリウム塩又は三カリウム塩等が挙げられる。
Adenosine triphosphate, adenosine diphosphate, and adenosine monophosphate (hereinafter referred to as ATP, ADP, and AMP, respectively) used as the component (B) of the present invention are substances involved in the energy transfer system and the generation system in vivo. It is. In the present invention, in addition to these ATP, ADP and AMP, derivatives thereof such as salts and esters thereof can be used. For example, monosodium salt, disodium salt, trisodium salt, monosodium salt of ATP, ADP or AMP can be used. A potassium salt, a dipotassium salt, a tripotassium salt, etc. are mentioned.

これら(B)成分は、一種又は二種以上を組合わせて用いることができ、また、シワ改善剤の改善作用及び経時安定性の点から、全組成中に0.0001〜10%、特に0.001〜1%配合するのが好ましい。 These components (B) can be used singly or in combination of two or more, and from the viewpoint of the improving action of the wrinkle improving agent and the stability over time, 0.0001 to 10%, especially 0 It is preferable to add 0.001 to 1%.

本発明のシワ改善剤は、常法に従い、必須成分であるオクラ(Hibiscus
esculentus)の種子から抽出された少なくとも1つの可溶性タンパク質画分及び細胞賦活剤とを通常の皮膚外用剤として知られる種々の形態の基剤に配合して調製することができる。
The wrinkle improving agent of the present invention is an essential ingredient Okra (Hibiscus) according to a conventional method.
esculentus) can be prepared by blending at least one soluble protein fraction extracted from seeds and a cell activator with various forms of bases known as normal skin external preparations.

シワ改善剤の形態の例としては、特に限定されず、例えば、乳液、クリーム、化粧水、パック、ファンデーション、洗浄料等の化粧品の他、分散液、軟膏剤、クリーム、外用液剤などとすることができる。 Examples of the form of the wrinkle improving agent are not particularly limited. For example, in addition to cosmetics such as emulsions, creams, lotions, packs, foundations, cleaning agents, etc., dispersions, ointments, creams, liquids for external use, etc. Can do.

外用剤の基剤としては、これら外用剤の形態に応じた基剤、例えば、通常の皮膚外用剤に用いられる水性成分、粉体、界面活性剤、油剤、保湿剤、低級アルコールや多価ルコール等のアルコール類、pH調整剤、防腐剤、色素、酸化防止剤、紫外線吸収剤、増粘剤、香料、美容成分等を必要に応じて配合することができる。 As a base for external preparations, bases according to the form of these external preparations, for example, aqueous components, powders, surfactants, oils, moisturizers, lower alcohols and polyhydric alcohols used in normal skin external preparations Alcohols such as pH adjusters, preservatives, dyes, antioxidants, ultraviolet absorbers, thickeners, fragrances, cosmetic ingredients, and the like can be blended as necessary.

本発明のシワ改善剤は、安全性が高く、かつシワ改善 作用に優れる。また、本発明
の皮膚化粧料は、皮膚のシワを改善する効果に優れると共に、皮膚に対して弊害なく安全に使用することができる。
The wrinkle improving agent of the present invention is highly safe and has an excellent wrinkle improving action. In addition, the skin cosmetic of the present invention is excellent in the effect of improving skin wrinkles and can be safely used without any harmful effects on the skin.

次に本発明を実施例を挙げて詳細に説明するが、本発明は以下の実施例により限定されるものではない。 EXAMPLES Next, although an Example is given and this invention is demonstrated in detail, this invention is not limited by a following example.

蒸留水25.0kgにオクラ(Hibiscus
esculentus)の全種子を粉砕して得られた全穀2.5kgを攪拌しながら分散することし、15分間の分散後、NaOH 4NでpH9に調節する。室温で2時間攪拌しながら抽出後、10分間遠心分離(回転数5,000g)し、濁ったベージュ色の上澄み液を回収する。H2SO4 4Nの添加によってpH7.5に調節し、遠心分離する。清澄化し、 乳光色の上澄み液を回収する。0.5μmで濾過しスプレードライする。スプレー収率は62.7重量%でありこれを、オクラ(Hibiscus
esculentus)の種子可溶性タンパク質画分とした。
Okra (Hibiscus) to 25.0 kg of distilled water
The whole grain obtained by grinding all seeds of esculentus) is dispersed while stirring, and after dispersion for 15 minutes, the pH is adjusted to 9 with NaOH 4N. After extraction with stirring for 2 hours at room temperature, the mixture is centrifuged for 10 minutes (revolution: 5,000 g), and a turbid beige supernatant is recovered. Adjust to pH 7.5 by addition of H 2 SO 4 4N and centrifuge. Clarify and collect the opalescent supernatant. Filter at 0.5 μm and spray dry. The spray yield was 62.7% by weight, which was converted to okra (Hibiscus).
esculentus) seed soluble protein fraction.

<本発明のシワ改善剤の評価>
表1に記載した試料を用いて、ヘアレスマウス(5週齢、雌)のUVシワモデル改善試験を行うことにより、本発明のシワ改善剤を評価した。
<Evaluation of the wrinkle improving agent of the present invention>
The wrinkle improving agent of the present invention was evaluated by conducting a UV wrinkle model improvement test on hairless mice (five weeks old, female) using the samples described in Table 1.

1群10匹ずつのヘアレスマウスの背部皮膚にUVB(60mJ/cm2)を、1日1回、1週間に5日の割合で照射し、9週間後、背部皮膚にシワが形成されていることを確認した。その後、上記実施例2、比較例1、2、3 それぞれを、表1に示す濃度で含有する60%エタノール水溶液100μLを、1日1回、1週間に5日の割合で上記ヘアレスマウスのシワ形成部位に塗布した。塗布開始から9週間後に皮膚のシワの改善程度を下記判定基準に従い、肉眼で評価した。 UVB (60 mJ / cm 2 ) was irradiated on the back skin of 10 hairless mice per group once a day at a rate of 5 days per week, and after 9 weeks, wrinkles were formed on the back skin. It was confirmed. Thereafter, 100 μL of a 60% ethanol aqueous solution containing each of Example 2 and Comparative Examples 1, 2, and 3 at the concentrations shown in Table 1 was added once a day at a rate of 5 days per week. It was applied to the formation site. Nine weeks after the start of application, the degree of improvement of skin wrinkles was evaluated with the naked eye according to the following criteria.

(判定基準)
− : シワ改善 効果が認められない
± : ややシワ改善 効果が認められる

: シワ改善 効果が認められる。
(Criteria)
−: Wrinkle improvement effect is not recognized ±: Wrinkle improvement effect is slightly recognized +
: Wrinkle improvement effect is recognized.

また、コントロールとして60%エタノール水溶液のみを上記同様にUVB照射後のヘアレスマウスに塗布したときのシワの改善程度を評価した。結果を表1に示す。 Further, as a control, the degree of wrinkle improvement when only a 60% ethanol aqueous solution was applied to hairless mice after UVB irradiation was evaluated in the same manner as described above. The results are shown in Table 1.

Figure 2006096730
Figure 2006096730

この結果から明らかなように、実施例2のシワ改善剤は比較例1、2、3に比べヘアレスマウスのUVシワモデル改善試験において、皮膚のシワを改善する効果に著しく優れることが確認された。なお、実験中のヘアレスマウスに発赤等の皮膚状態の悪化等は全く確認されず、本発明のシワ改善剤は安全性にも問題がないことがわかった。 As is clear from this result, it was confirmed that the wrinkle improving agent of Example 2 was remarkably superior in the effect of improving skin wrinkles in the UV wrinkle model improvement test of hairless mice as compared with Comparative Examples 1, 2, and 3. . In addition, no deterioration of skin condition such as redness was observed in hairless mice during the experiment, and it was found that the wrinkle improving agent of the present invention has no safety problem.

次に、上記実施例で得られたシワ改善剤を配合した本発明の皮膚化粧料の実施例について説明する。なお、以下に用いる配合量はすべて重量%である。 Next, examples of the skin cosmetics of the present invention in which the wrinkle improving agent obtained in the above examples is blended will be described. In addition, all the compounding quantities used below are weight%.

実施例3クリーム:表2に示す処方で以下の製法でクリームを調整した。A成分を80℃に加熱混合した。また、A成分とは別にB成分を80℃に加熱混合した。ついで、A成分にB成分を加えて撹拌乳化した後、これを35℃まで冷却して、上記実施例2のシワ改善剤を混合し水中油クリームを得た。また、同様にして本発明のシワ改善剤を精製水と置き換えたクリーム(比較例4)を作製した。   Example 3 Cream: A cream was prepared according to the formulation shown in Table 2 by the following method. A component was heated and mixed at 80 degreeC. Separately from component A, component B was heated and mixed at 80 ° C. Subsequently, the B component was added to the A component and emulsified with stirring, and then cooled to 35 ° C., and the wrinkle improving agent of Example 2 was mixed to obtain an oil-in-water cream. Similarly, a cream (Comparative Example 4) in which the wrinkle improving agent of the present invention was replaced with purified water was produced.

Figure 2006096730
Figure 2006096730

<本発明の皮膚化粧料の評価>
上記実施例2および比較例4で得られたクリームを用いて実使用テストを行い、本発明の皮膚化粧料についてのシワ改善効果を評価した。
<Evaluation of skin cosmetics of the present invention>
An actual use test was performed using the creams obtained in Example 2 and Comparative Example 4 above, and the wrinkle improving effect of the skin cosmetic of the present invention was evaluated.

目尻に明瞭なシワおよびシミを有する男女10名にパネラーとして半顔テストを行った。実験に先立ってパネラー全員の左右の目尻の様子をそれぞれ写真に撮影した。その後、パネラーの左右の目尻の一方には、実施例2の水中油クリームを、他方の目尻には比較例4のクリームを、それぞれ通常の方法で1日2回、8週間にわたり連続して使用してもらった。使用開始から12週間後、実験開始前と同様に、パネラー全員の左右の目尻の様子をそれぞれ写真に撮影した。この様にしてパネラー1名について、目尻の左右、実験の前後で計4枚の写真が得られ、これを用いて以下の方法で評価を行った。 Half face tests were conducted as panelists on 10 men and women with clear wrinkles and spots in the corners of their eyes. Prior to the experiment, we photographed each panel's left and right eye corners. Thereafter, the oil-in-water cream of Example 2 was used on one of the left and right corners of the panel, and the cream of Comparative Example 4 was continuously used on the other corner, twice a day for 8 weeks. I was asked to. After 12 weeks from the start of use, the left and right eye corners of all panelists were photographed in the same manner as before the start of the experiment. In this manner, a total of four photographs were obtained for one panelist before and after the experiment, before and after the experiment, and evaluated using the following method.

上記パネラー以外の第三者に、実験の内容に関して一切の情報を与えないまま、あるパネラーについての右側の目尻を実験前後に撮影した2枚の写真を見せて、2枚の写真のうちどちらか1枚をシワの少ない状態として選択してもらった。選択してもらった写真が使用後の写真であれば、このパネラーが右目尻に使用したクリームは、シワ改善
効果有りと評価し、使用前の写真であれば自然増悪として評価した。また、選択できない場合には効果なしと判定した。その後、上記パネラーの左側の目尻を実験前後に撮影した2枚の写真を同様に比較してもらい、このパネラーが左目尻に使用したクリームについての評価を行った。さらに、他の9人のパネラーの写真を用いて各クリームのシワ改善効果を同様に評価した。結果を表3にまとめた。
Without giving any information about the contents of the experiment to a third party other than the above paneler, show two photos taken before and after the experiment on the right corner of a paneler, and either one of the two photos One was chosen as a state with few wrinkles. If the selected photo was a post-use photo, the cream used by this paneler on the right eye corner was evaluated as having a wrinkle-improving effect, and the pre-use photo was evaluated as a natural exacerbation. When it was not possible to select, it was determined that there was no effect. Thereafter, two photographs taken before and after the experiment of the left corner of the panel were compared in the same manner, and the cream used for the left corner of the panel was evaluated. Furthermore, the wrinkle improvement effect of each cream was similarly evaluated using the photographs of the other nine panelists. The results are summarized in Table 3.

Figure 2006096730
Figure 2006096730

この結果から明らかなように、本発明のシワ改善剤を含有する実施例3のクリームは、本発明のシワ改善剤を含有しない比較例のクリームに比べて、シワの改善効果に関して評価内容が良好であった。なお、上記実験における各クリームの使用期間中、肌の発赤や肌荒れ等のトラブルを訴えるパネラーはひとりもいなかった。 As is clear from the results, the cream of Example 3 containing the wrinkle improving agent of the present invention has a better evaluation content regarding the wrinkle improving effect than the cream of the comparative example not containing the wrinkle improving agent of the present invention. Met. During the period of use of each cream in the above experiment, no panelists complained of problems such as skin redness and rough skin.

以下に処方例を示すが、本発明はこれに限定されるものではない。 Although a formulation example is shown below, this invention is not limited to this.

(化粧水)

Figure 2006096730
(Lotion)
Figure 2006096730

(乳液)

Figure 2006096730
(Milky lotion)
Figure 2006096730

(美容液)

Figure 2006096730
(Cosmetic liquid)
Figure 2006096730

優れたシワ改善効果を有し、安全性をも有した皮膚化粧料の提供を可能とする。
It is possible to provide a skin cosmetic that has an excellent wrinkle improvement effect and also has safety.

Claims (2)

(A)オクラ(Hibiscus esculentus)の種子からの少なくとも1つのタンパク質画分と、(B)細胞賦活剤とを有効成分として含有することを特徴とするシワ改善剤。 (A) A wrinkle improving agent comprising at least one protein fraction from seeds of Okra (Hibiscus esculentus) and (B) a cell activator as active ingredients. 細胞賦活剤が、デオキシリボ核酸及びその塩、アデノシン三リン酸
、アデノシン一リン酸などのアデニル酸誘導体及びそれらの塩、リボ核酸及びその塩、グアニンの誘導体並びにそれらの塩などの核酸関連物質から選ばれる請求項1記載のシワ改善剤。
The cell activator is selected from nucleic acid-related substances such as deoxyribonucleic acid and salts thereof, adenylic acid derivatives and salts thereof such as adenosine triphosphate and adenosine monophosphate, ribonucleic acid and salts thereof, guanine derivatives and salts thereof The wrinkle improving agent according to claim 1.
JP2004288160A 2004-09-30 2004-09-30 Wrinkle-improving agent Pending JP2006096730A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004288160A JP2006096730A (en) 2004-09-30 2004-09-30 Wrinkle-improving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004288160A JP2006096730A (en) 2004-09-30 2004-09-30 Wrinkle-improving agent

Publications (1)

Publication Number Publication Date
JP2006096730A true JP2006096730A (en) 2006-04-13

Family

ID=36236878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004288160A Pending JP2006096730A (en) 2004-09-30 2004-09-30 Wrinkle-improving agent

Country Status (1)

Country Link
JP (1) JP2006096730A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009139335A (en) * 2007-12-10 2009-06-25 Shiseido Co Ltd Cultured skin wrinkle model, its manufacturing method, and antiwrinkle medicine evaluation method
WO2011162416A1 (en) * 2010-06-25 2011-12-29 Otsuka Pharmaceutical Co., Ltd. Agent for suppressing the formation of abnormal skin cells caused by exposure to light
KR101480693B1 (en) * 2008-04-14 2015-01-09 (주)아모레퍼시픽 Anti-aging cosmetic composition for skin
CN105342904A (en) * 2015-11-02 2016-02-24 嘉文丽(福建)化妆品有限公司 Essence with skin anti-wrinkle effect
CN113876650A (en) * 2021-07-06 2022-01-04 上海瑞帝安生物科技有限公司 Cosmetic composition containing germination exudates of okra

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009139335A (en) * 2007-12-10 2009-06-25 Shiseido Co Ltd Cultured skin wrinkle model, its manufacturing method, and antiwrinkle medicine evaluation method
KR101480693B1 (en) * 2008-04-14 2015-01-09 (주)아모레퍼시픽 Anti-aging cosmetic composition for skin
WO2011162416A1 (en) * 2010-06-25 2011-12-29 Otsuka Pharmaceutical Co., Ltd. Agent for suppressing the formation of abnormal skin cells caused by exposure to light
JP2013529628A (en) * 2010-06-25 2013-07-22 大塚製薬株式会社 Inhibitor of skin cell abnormality due to light exposure
US9125928B2 (en) 2010-06-25 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Agent for suppressing the formation of abnormal skin cells caused by exposure to light
CN105342904A (en) * 2015-11-02 2016-02-24 嘉文丽(福建)化妆品有限公司 Essence with skin anti-wrinkle effect
CN113876650A (en) * 2021-07-06 2022-01-04 上海瑞帝安生物科技有限公司 Cosmetic composition containing germination exudates of okra
KR20230007836A (en) * 2021-07-06 2023-01-13 주식회사 래디안 Cosmetic composition comprising germinated okra exudate
KR102555539B1 (en) 2021-07-06 2023-07-13 주식회사 래디안 Cosmetic composition comprising germinated okra exudate
CN113876650B (en) * 2021-07-06 2023-10-20 上海瑞帝安生物科技有限公司 Cosmetic composition containing okra sprouting exudates

Similar Documents

Publication Publication Date Title
CN103547254B (en) Containing the wrinkle improvement compositions from the composition of Placenta Hominis
CN105476950B (en) Moisturizing foam mildy wash and preparation method thereof
JP2000016917A (en) Skin whitening cosmetic
JP3513872B2 (en) External preparation for skin
JP5765744B2 (en) Preventive or therapeutic agent for atopic dermatitis, and external preparation
JP2001097828A (en) Cosmetic for hair
JPH049316A (en) Whitening cosmetic
JP2006096730A (en) Wrinkle-improving agent
JP7075177B2 (en) Cosmetics
JPH10158181A (en) Lipolysis promoter and skin cosmetic for weight reduction
JP7534759B2 (en) Antioxidants, antiglycation agents, hyaluronidase inhibitors, and cosmetics
CN106727255B (en) Shampoo containing natural surfactant and preparation method thereof
JP3502808B2 (en) Cosmetics
JPH0899860A (en) Skin external agent
JP2002284632A (en) Extinction substance for superoxide anion extracted from sake lees as effective component
JP2001114635A (en) Cosmetic composition containing extract of muscovado
JPH04321615A (en) Skin medicine for external use
JPH09315930A (en) Cosmetic material for skin
JP2009209063A (en) Skin preparation for external use, or skin cosmetic
JP3076620B2 (en) External preparation for skin
JP2004035425A (en) Ameliorant for dropsy
JP2001288048A (en) Composition for scalp and hair
JP3101090B2 (en) External preparation for skin
JP2021169532A (en) Transglutaminase production promoter
JP2855274B2 (en) Hair restoration